化工儀器網
公司動態
ABL.inc公司品牌介紹/代理商/試劑盒現貨
閱讀：2435 發布時間：2018-1-19
Advanced BioScience Laboratories公司簡稱ABL
Advanced BioScience Laboratories, Inc （ABL） 是馬里蘭州的生物醫學研究公司，專責為生物醫學團體提供資源開發和評估各種疫苗，治療和診斷傳染源。ABL是一個高度專業的合同研究組織（CRO ）,具有與政府，商業和其他團體合作的豐富經驗。ABL致力于預防艾滋病毒和傳染病的研究。ABL可以幫助各個領域的產品開發，包括：基礎研究，疫苗或產品設計，具有免疫調控的動物模型，為*階段和第二階段的臨床試驗生產cGMP生物制品以及許多其他服務。
ABL有著數以百計的出版物和在艾滋病毒和傳染病領域幾十年的研究經驗。
ABL有著悠久的歷史，為客戶提供免疫調控服務（ ELISA方法，抗原表位的映射，免疫印跡，淋巴細胞的分離，流式細胞儀， elispot等） ，細胞庫，并擴增和QC病毒（HIV, SIV, Vaccinia, CMV, HTLV, and FIV）和雜交瘤。
ABL還可以提供一系列廣泛的病毒學檢測方法的研究使用，如通過NASBA進行RNA的病毒載量測試，抗病毒和病毒中和試驗,RIPA，抗原捕獲，檢測的RT和其它許多相關服務。
ABL還針對HIV，SIV和病毒學研究提供各種特殊產品，包括抗體，抗原，高免疫血清，病毒原液和抗原捕獲試劑盒。 ABL’s MissionABL’s mission is to provide integrated product development services at the highest quality to advance client products from target discovery to IND.ABL’s History
1961 Company established as Bionetics Research Laboratories (BRL), conducting biomedical research for the U.S. Government.
1968 Acquired by Litton Industries and renamed Litton Bionetics, Inc. (LBI). Company began expanding activities in the areas of retrovirus and cancer research.
1985 LBI acquired by Organon Teknika n.v., a subsidiary of Akzo Nobel, Inc. U.S. Government support laboratories renamed Advanced BioScience Laboratories, Inc. (ABL).
2001-2004 ABL acquired by bioMerieux, Inc. and later spun out under the Institut Mérieux as an independent U.S. corporation. During this time, ABL continues to develop product development services against a broad array of infectious disease and immune-based disease targets.
2011 ABL moved into a new corporate headquarters and state-of-the-art cGMP facility in Rockville, MD.
2014 ABL invested in clinical services through the acquisition of Platine Pharma Solutions, SA (Lyon, France) and build-out of a dedicated GCLP clinical testing laboratory in Rockville.
2015 ABL Europe, a wholly-owned subsidiary of ABL, Inc. formed to lead ABL manufacturing operations in Europe.
2016 ABL significantly expands its cGMP capABIlity by acquiring a manufacturing plant from Transgene, SA (Strasbourg, France) for the production of virus-based gene therapies, oncolytics and vaccines. This facility, managed by ABL Europe, has been inspected and approved for GMP operations by the ANSM, maintains multiple bulk productions suites, a high-speed isolator-based aseptic fill/finish line, and QC laboratories for development and execution of product release and stABIlity studies.